INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 434m ago
HOUSE PTR33m ago
SEC 13F33m ago
ROBINHOOD CHAIN33m ago
SEC FORM 4/Grant or awardVerified data

Phillips Andrew John reported OKUR

Director · OnKure Therapeutics, Inc. · OnKure Therapeutics, Inc. — Stock Option (right to buy)

Side
A
Value
—
Shares
7,650
Price
—
Executed
Jun 4, 2026
Disclosed
Jun 8, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jun 4 executedJun 8, 2026 disclosed

OKUR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · OKUR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    26
    LA
    Leverone Jason A.Chief Financial Officer
    OKUROnKure Therapeutics, Inc.
    Open-market sale
    		SELL$898
    302 sh
    		Sep 21, 2026Sep 23, 2026
    traded Sep 21, 2026
    		+2dSEC FORM 4

    Evidence

    26
    SA
    Saccomano Nicholas ADirector, President and CEO
    OKUROnKure Therapeutics, Inc.
    Open-market sale
    		SELL$259
    87 sh
    		Sep 21, 2026Sep 23, 2026
    traded Sep 21, 2026
    		+2dSEC FORM 4

    Evidence

    9
    HD
    Hartley DylanChief Scientific Officer
    OKUROnKure Therapeutics, Inc.
    Disposition to issuer
    		D—
    137.6K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    HD
    Hartley DylanChief Scientific Officer
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    137.6K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    PJ
    Phillips Andrew JohnDirector
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    22.4K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AS
    Agresta SamuelChief Medical Officer
    OKUROnKure Therapeutics, Inc.
    Disposition to issuer
    		D—
    18.6K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AS
    Agresta SamuelChief Medical Officer
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    18.6K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AS
    Agresta SamuelChief Medical Officer
    OKUROnKure Therapeutics, Inc.
    Disposition to issuer
    		D—
    131.4K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AS
    Agresta SamuelChief Medical Officer
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    50.0K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AS
    Agresta SamuelChief Medical Officer
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    131.4K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    HD
    Hartley DylanChief Scientific Officer
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    50.0K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    JM
    Jansen Valerie MalyvanhDirector
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    22.4K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    JM
    Jansen Valerie MalyvanhDirector
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    7,650 sh
    		Jun 4, 2026Jun 8, 2026
    traded Jun 4, 2026
    		+4dSEC FORM 4

    Evidence

    9
    HD
    Hartley DylanChief Scientific Officer
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    110.0K sh
    		Apr 1, 2026Apr 3, 2026
    traded Apr 1, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001921956-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 4, 2026
    Published
    Jun 8, 2026
    Ingested by INSIDER
    Nov 5, 03:54 UTC
    Last re-read
    Nov 5, 03:54 UTC

    Extracted facts

    Filer
    Phillips Andrew John
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    OnKure Therapeutics, Inc. — Stock Option (right to buy)
    Ticker
    OKUR
    Shares
    7,650
    Price per share
    $0
    Execution date (reported)
    Jun 4, 2026
    Owned after transaction
    7,650 shares
    Days from execution to publication
    4

    What this establishes

    Phillips Andrew John filed this Form 4 reporting a grant or award of OKUR on Jun 4, 2026. It became public on Jun 8, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Phillips Andrew Johncik:0001921956
    Issuer
    OnKure Therapeutics, Inc.cik:0001637715

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.